A 30-Day Supply of RESTASIS® is 2 Trays — 60 Vials Total

The approved dosage for RESTASIS® Ophthalmic Emulsion is 1 drop in each eye in the morning and 1 drop in each eye in the evening. Vials should be discarded after each use. Therefore, a patient will need 2 vials a day. When used as approved, 2 trays (60 vials) is the recommended 30-day supply of RESTASIS®.

Now $38 Average Commercial Co-pay

Helping more patients make more of their own real tears for less

  • Tier 2/preferred status and a $28 average commercial insurance co-pay make RESTASIS® affordable for even more patients as of January 2010*†1,2
  • The recent drop to a $29 average Part D co-pay provides additional affordability as of January 2010*†2
  • Insurance coverage for RESTASIS® includes 98% of commercial and Part D member lives as of February 2010*3
  • WellPoint, Humana, Medco, Caremark, and Aetna now offer Tier 2 or preferred coverage for RESTASIS®, bringing the total to 126 million lives on select commercial and Part D plans as of February 2010*‡3


*Plans may vary. Not all patients have health insurance coverage.
†Average calculated using all approved claims, all days supply, exclusive of zero/null co-pay values.
‡Aetna Part D uses a 5-Tier formulary with preferred brand-name products covered at Tier 3.

Indication and Usage: RESTASIS® Ophthalmic Emulsion is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.

Important Safety Information:

Contraindications: RESTASIS® is contraindicated in patients with active ocular infections and in patients with known or suspected hypersensitivity to any of the ingredients in the formulation.

Warning: RESTASIS® Ophthalmic Emulsion has not been studied in patients with a history of herpes keratitis.

Precautions: RESTASIS® should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to the administration of the emulsion.

Adverse Reactions: The most common adverse event was ocular burning (upon instillation) – 17%. Other events reported in 1% to 5% of patients included conjunctival hyperemia, discharge, epiphora, eye pain, foreign body sensation, pruritus, stinging, and visual disturbance (most often blurring).

Please see full prescribing information for RESTASIS® Ophthalmic Emulsion.

References
  1. Mullins CD, Palumbo FB, Saba M. Formulary tier placement for commonly prescribed branded drugs benchmarking and creation of a preferred placement index. Am J Manag Care. 2007;13:377-384.
  2. Average Monthly Co-pay Data. Wolters Kluwer Pharma Solutions, Source® Dynamic Claims, January 2010.
  3. MediMedia Formulary Compass Database, February 2010.